The ALAFOS Study

This study aims to monitoring fracture rate, quality of life and osteoporosis knowledge in women on Forteo.  Most available treatments for osteoporosis are designed to decrease bone loss but do not replace the bone that was lost. In contrast, teriparatide (Forteo®) can stimulate the build-up of new bone. This research is being conducted by Eli Lilly and Company.  ALAFOS is an international study and has four study sites within Australia.

Study Details

For further enquiries please contact